For subscribers
A riskier approach to new vaccines will pay off
Investing more money in the next Covid-19 vaccine is not only likely to create scientific spillovers for other vaccines but is also the best way we have of reducing the risk of disaster
Sign up now: Get ST's newsletters delivered to your inbox
A lab employee working on the SKYCovione vaccine at SK Bioscience’s R&D centre in South Korea.
PHOTO: BLOOMBERG
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Tim Harford
(FINANCIAL TIMES) - At the risk of sounding like a newlywed presenting my spouse with a list of pointers for improvement, these once-miraculous Covid-19 vaccines could do better. It wasn't long ago that I celebrated the anniversary of being fully vaccinated, but that first flush of immunity started to wane very quickly. I've even been flirting with some exciting new variants.
I shouldn't joke. The vaccines were indeed spectacularly effective, as well as being as safe as one could hope. But the virus has adapted so quickly that it is at risk of leaving us behind.
